Final-Program-ATS-2023-AP.vp

MONDAY • MAY 22

129

9:00 Utilizing Complementary Murine Models of Experimental Sepsis to Determine How Age Increases the Virulence of Gut-Derived Pathogens J. Colbert, MD, Aurora, CO 9:20 Preserved Alternative Complement Function is Associated with Improved Survival During ARDS: A Translational Perspective W. Bain, MD, Pittsburgh, PA 9:40 A Clinically Relevant Mouse Model of Sepsis-Induced Delirium J.A. Bastarache, MD, Nashville, TN 10:00 Red Cell-DNA Delivery Contributes to the Heterogeneous Host Response in Sepsis N.S. Mangalmurti, MD, Philadelphia, PA 10:20 Cytokine Networks That Limit Infection-Induced Inflamation C. Hunter, PhD, Philadelphia, PA

9:40 Actions Speak Out Louder Than Policies: Institutional Variation in Holding Patients Accountable for Inappropriate Behaviors E.M. Viglianti, MD, MPH, MSc, Ann Arbor, MI 9:50 Pay to Stay: How Do Funding Agencies Support DEI Faculty? .A. Bernard, MD, Washington, DC 10:05 When Color Blindness Is Not an Option - What Institutions Can Do to Recruit, Promote and Retain URiM V. Asare, MD, New Haven, CT 10:15 Panel Discussion J.C. Celedon, MD, DrPH, ATSF, Pittsburgh, PA

BASIC • TRANSLATIONAL BASIC SCIENCE CORE CME Credits Available: 1.5

CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM CME Credits Available: 1.5

B5

BACK TO BASICS: HARNESSING THE POWER OF MOUSE MODELS TO UNDERSTAND HUMAN SEPSIS

Assemblies on Allergy, Immunology and Inflammation; Critical Care; Pulmonary Circulation; Respiratory Cell and Molecular Biology 9:00 a.m. - 10:30 a.m. Target Audience Basic, translational, and clinical scientists Objectives At the conclusion of this session, the participant will be able to: • describe new mechanistic insights into human sepsis derived from pre-clinical mouse models • understand and identify perceived and actual barriers to translating pre-clinical findings to the clinic • identify new strategies to limit infection-induced inflammation Sepsis, the dysregulated host response to infection, is a life-threatening clinical syndrome affecting all cells, tissues, and organs. While no pre-clinical model can recapitulate the myriad complexities of organ dysfunction and tissue injury in human sepsis, animal models are essential to developing a mechanistic understanding of sepsis and identifying novel targets for intervention. This symposium will provide attendees with a basic overview of commonly used mouse models of sepsis, with an emphasis on how these models provided new insights directly relevant to human sepsis. Chairing: J.A. Bastarache, MD, Nashville, TN

B6

NON-PAP ALTERNATIVES FOR OSA: FROM ACCEPTED TO REVOLUTIONARY

Assembly on Sleep and Respiratory Neurobiology 9:00 a.m. - 10:30 a.m. Target Audience Clinicians and researchers interested in Obstructive Sleep Apnea (OSA) therapies Objectives At the conclusion of this session, the participant will be able to: • understand better current and future approaches to optimal patient selection for available OSA therapies • describe recent progress and challenges in the (pre)clinical development of new drug/device therapies • describe regulatory requirements to translate interventions into FDA-approved clinical therapies While CPAP can have transformative effects for some patients with obstructive sleep apnea (OSA), many patients are unable to tolerate PAP therapy long-term and due to limited alternatives remain untreated. Based on recent publications and conference sessions, there is a clear need for novel, personalized treatment options. Through state-of-the-art reviews and an in-depth panel discussion, we will provide the audience with current best practices for more established therapies (e.g. oral appliances, hypoglossal nerve stimulation) and speak to critical issues including regulatory considerations for the development of novel, personalized alternative therapies (e.g. ansa cervicale stimulation, endotype-targeted drug therapy, DREADD).

N.S. Mangalmurti, MD, Philadelphia, PA E.P. Schmidt, MD, ATSF, Boston, MA

ATS 2023 • Washington, DC